Jeffrey Hung, Ph.D.
Jeffrey has over 20 years of experience in the biotechnology industry. He joined Vigene in 2016 and orchestrated the acquisition of Omnia Biologics. He has also overseen Vigene’s expansion into GMP manufacturing and new product areas such as biosensors. An experienced entrepreneur, Jeffrey was instrumental in successfully growing GenScript and SABiosciences, two previous companies, to IPO and acquisition stage, respectively. He also previously held the position of Chief Marketing Officer at ATCC. Jeffrey is the author of multiple patents, publications, and book chapters. He holds a Ph.D. in genetics from Cornell University, an MBA from UC Berkeley, and a B.S. in biology from Peking University.
Zairen Sun, Ph.D.
Zairen has over 20 years of experience in the biotechnology industry. He founded Vigene Biosciences in 2012 with the focus of aiding research to cure human diseases through gene therapy and cell therapy. Prior to founding Vigene Biosciences, Zairen was the head of R&D at OriGene Technologies Inc. During his 14-year tenure at OriGene, Zairen and his team created the most comprehensive collection of human full-length cDNA clones and their derivative products like proteins and antibodies. Zairen has many patents and publications. He holds a Ph.D. degree in molecular biology from the University of Maryland at College Park.
Audrey Chang, Ph.D.
Audrey Chang Ph.D. earned her PhD in Biology at The Johns Hopkins University; Baltimore Maryland and has over 25 years of government and industry experience in conducting biological products testing and in managing laboratories. In her current role as Vice President of QC and Analytical Development at Vigene Biosciences, she is responsible for managing and developing a team scientific experts that provides greater focus to the development of new services and technologies while providing technical solutions and support to clients and operating laboratories.
Patrick has over 25 years of experience in the pharmaceutical/biotech industry and has held positions in Research & Development, Quality Control/Quality Assurance and for the last 17+ years in Business Development, all of which have been in the Contract Development and Manufacturing space.
Patrick joined Vigene in 2020 as Vice President of Business Development. Prior to joining Vigene, Patrick held Senior Business Development positions at Emergent BioSolutions, Catalent/Aptuit and Azopharma. Patrick earned his Bachelor of Science from Fredonia State University (ACS accredited) and a Master of Science in Analytical Chemistry (LC/MS) from Clemson University.
Chien-Chien Jacques, CPA
CC is an actively licensed CPA with over 15 years of finance and accounting experience across a variety of industries but has been focused in Biotech for the last 8 years. She joined Vigene in May 2019. Prior to joining Vigene, CC was the Controller of the US Division of Immunodiagnostic Systems (IDS) headquartered in the United Kingdom. CC earned her Bachelor of Science degree from the University of Maryland, College Park as well as a Master of Science in Accounting and Financial Management.
James has over 20 years of experience in quality systems with extensive cGMP knowledge. He joined Vigene in January 2018 and oversees the Quality Assurance group supporting cGMP manufacturing. Previously James was at AstraZeneca where he held both Quality Control and Quality Assurance positions of increasing responsibilities within the quality network. James holds a B.S. in Chemistry from University of Southern Maine and held certifications for both ASQ Quality Manager and Quality Auditor. He also proudly served in the US Navy for 4 years.
Jenny Qinghua Zhao
Jenny joined Vigene in April 2019 as a Director (now Senior Director) of Manufacturing Science and Technology (MSAT) and has led the Downstream Process Development since February 2020 that now includes Vigene’s expansion into new GMP sites. Jenny has over 20 years of experience in the biopharma industry including Mab/IND at SalubrisBio, BLA approval of Fremanezumab/ AJOVY at Teva Pharmaceutical, PD-1 Mab at Amplimmune (now AstraZeneca), TNFerade (Ad5 gene therapy phase 3) at GeneVec, ENBREL (etanercept) in Wyeth (now Pfizer), fusion proteins at HGS (now GSK). Ms. Zhao earned her master’s degree of Chemical Engineering from University of Waterloo in Canada.